US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Allenex acquires all remaining minority interests in the group

Allenex AB (publ) (”Allenex”) has signed an agreement to acquire all SSP Primers AB’s ("SSP Primers") shares in Olerup SSP AB, AbSorber AB, Olerup International AB and Olerup Inc. The acquisition will make Allenex the sole owner of all companies in the Allenex group. At the same time, Allenex acquires SSP Primers’ claim on Olerup Inc. of about 4 million SEK. These acquisitions are financed by loans made available by the company's main bank and by payments from Allenex to SSP Primers over a period of three years.Pursuant to the agreement Allenex acquires 9% of Olerup SSP AB, 1.9% of AbSorber

Olerup SSP extends its product portfolio through a new exclusive sales agreement

LinkMed’s transplantation company, Olerup SSP, has signed an exclusive sales agreement with the American company Biotium for their product GelRed™. The sales agreements gives Olerup SSP the exclusive rights to sell GelRed™ to the HLA typing market. GelRed™ is an environmentally safe and ultrasensitive fluorescent nucleic acid gel stains designed to replace the highly toxic ethidium bromide (EtBr).Developed by Biotium, GelRed™ is superior to EtBr and other EtBr alternatives by having a combination of low toxicity, high sensitivity and exceptional stability. GelRed™ is a sensitive, stable and

Increased focus on the transplantation sector

The Board of Directors of LinkMed today announced a strategic decision to further focus the company’s operations on the transplantation sector. Consequently, LinkMed will work actively to find additional acquisitions in the sector and continue its global efforts in Olerup SSPs and AbSorber’s product area. Going forward, LinkMed will prioritize investment in this sector. At the same time, the company will intensify work to realize the value of the portfolio of life science companies built up since 1998. In the long-term, LinkMed’s operations will essentially be focused on the transplantation

Olerup SSP’s entire HLA typing range now ready for sales in the U.S.

Olerup SSP, a wholly owned subsidiary of LinkMed, has had its Taq-polymerase-free HLA typing kit registered and cleared by the FDA. This means that Olerup SSP’s entire product range for HLA typing, with or without Taq polymerase, can now be marketed and sold to a greater number of healthcare centers in North America. The U.S. is the single largest market for HLA typing and represents over 40 percent of the global tissue typing market. Olerup SSP’s HLA typing kit with Taq polymerase has been approved by the FDA for sale in the United States since March 2009.“Olerup SSP’s products are

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media